Doheny Researchers to Test Next-Generation Retinal Implant
CONNI BERGMANN KOURY, EDITOR-IN-CHIEF
Genetic Testing Sheds Light on Degenerative Eye Disease
The molecular definition of the genetic basis of disease provides a unique adjunct to the clinical care of patients with hereditary retinal degenerations.
RADHA AYYAGARI, PhD
New Combination Approaches Explored for AMD Management
There is a pharmacologic hypothesis for treatments addressing both biochemical and physical aspects of neovascular AMD.
MARK S. HUGHES, MD, AND DELIA N. SANG, MD
Bevacizumab Useful for the Treatment of Myopic CNV
Off-label treatment with bevacizumab may prove beneficial against other forms of CNV secondary to AMD.
ADAM H. ROGERS, MD, AND ELIAS REICHEL, MD
Retinopathy Predicts Cardiovascular Mortality in Patients With Type 2 Diabetes
There were signifincat differences, however, with regarding to sex-specific associations.
MARKKU LAAKSO, MD
Is Diabetic Retinopathy an Independent Risk Factor For Ischemic Stroke?
Diabetic retinopathy may help predict people who could require a more comprehensive assessment of their stroke risk.
TIEN Y. WONG, MD, PhD
Photographic Evidence of Vitreous Wicks After Intravitreal Injections
The prolapse of vitreous strands at the wound site has been noted after intravitreal injections.
PAUL M. BEER, MD; EMILY A. BEER; KIMBERLY E. STEPIEN, MD; NATALIE STANCIU, MD; AND NAOMI S. FALK, MD
Implants Can Deliver Corticosteroids, Pharmacologic Agents
Although intravitreal injections are very successful, the frequency with which they have to be used is a concern.
BARUCH D. KUPPERMANN, MD, PhD
New Developments in the Transscleral Delivery of Ophthalmic Agents
The profile of the drug being delivered is as important as the delivery method.
KARL G. CSAKY, MD, PhD
Drug Delivery to the Suprachoroidal Space Shows Promise
This novel approach uses a new-technology microcannulation system.
TIMOTHY OLSEN, MD
Determining the Cost-Effectiveness of Neovascular AMD Treatments
Jointly sponsored by The Dulaney Foundation and Retina Today Release Date: April 2007. Expiration Date: April 30, 2008. This continuing medical education activity is supported by an educational grant from Genentech.
MELISSA M. BROWN, MD, MN, MBA